Fresenius Kabi announces that the US FDA has granted expanded indication for SMOFlipid Lipid Injectable Emulsion (ILE) for pediatric patients, including term and preterm neonates. The product contains soybean oil, medium-chain triglycerides (MCT), olive oil, and fish oil, a source of omega-3 fatty acids. SMOFlipid can be used throughout the continuum of care, from the hospital to home care settings.